 |
| What is Type 1 diabetes? | What is the AIDA study? | How to Join | Clinical Centers and Locations | Contact Us | Home |
Where do I go?
AIDA Participating Clinical Centers - Italy, Switzerland, Netherlands
Screening and regular visits can occur at any of our Participating Clinical Centers below:
Italy
University Campus Bio-Medico, Rome
Dr Chiara Guglielmi
c.guglielmi@unicampus.it
University Campus Bio-Medico
Dept Endocrinology & Diabetes
Via Alvaro del Portillo 21
00128 Rome
ItalyP: +39 06 22541 9152
Switzerland
University Hospital Zürich, Zürich
Dr. Claudia Weder
claudia.weder@usz.chKlinik für Endokrinologie, Diabetologie & Klin. Ernährung
UniversitätsSpital Zürich
Rämistrasse 100
CH-8091 Zürich
Switzerland
P: 0041 4425 5 8732
Netherlands
Leiden University Medical Center, Leiden
E.J.P. de Koning
M.D., Ph.D.
e.dekoning@lumc.nl
Leiden University Medical Center
Department of Nephrology C3-P
Albinusdreef 2
2333 ZA Leiden
NetherlandsP: 0031 7152 6 9111
What is  |
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes. The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe. |
Supported by: The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers. The expenses of the trial are funded by grants from Juvenile Diabetes Foundation International, New York, USA, the world’s largest private diabetes fund. Funding also provided by Oresund Diabetes Academy and Steno Diabetes Center, Denmark. |
| Site Map | Contact Us | AIDA Locations | Accessibility | Contact the Web Master | AIDA Member Web Site | |
